Raul Cordoba, MD, PhD presents results from the phase 1 study of sonrotoclax plus zanubrutinib in relapsed/refractory mantle cell lymphoma, highlighting a favorable safety profile with no TLS or atrial fibrillation, and promising antitumor activity, including a 78% ORR and 70% CR rate at the RP2D of 320 mg.

COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION FOR PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Videos

Raul Cordoba, MD, PhD, presents results from the phase 1 study of sonrotoclax plus zanubrutinib in relapsed/refractory mantle cell lymphoma, highlighting a favorable safety profile with no tumor lysis syndrome or atrial fibrillation, and promising antitumor activity, including a 78% overall response rate and a 70% complete response rate at the recommended dose of 320 mg.

Combination Treatment With Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) and Zanubrutinib Induces High Rate of Complete Remission for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Raul Cordoba, MD, PhD, specialist, Hematology and Hemotherapy, coordinator, Lymphoma Unit, University Hospital Fundación Jiménez Díaz in Madrid, Spain, discusses efficacy data with epcoritamab observed in the phase 1/2 EPCORE NHL-2 trial (NCT04663347) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

The EPCORE NHL-2 trial evaluated the safety and preliminary efficacy of epcoritamab plus rituximab (Rituxan), dexamethasone, cytarabine, and oxaliplatin or carboplatin in patients with relapsed/refractory DLBCL who are eligible for autologous stem cell transplant (ASCT).

Data showed the combination elicited an overall response rate of 88%, which is  superior to the 40% to 50% response rates seen with chemotherapy alone in this patient population, Cordoba says. Notably, approximately two-thirds of patients achieved a complete response with the epcoritamab-based combination, Cordoba adds.

Although this response rate afforded more patients with the opportunity to undergo ASCT, half of patients on the trial elected not to receive ASCT, instead continuing epcoritamab monotherapy, Cordoba explains. At the time of data cutoff, half of patients remained on treatment, and half discontinued treatment due to disease progression or adverse effects, Cordoba concludes.

Raul Cordoba, MD, PhD, discusses efficacy data with epcoritamab observed in the phase 1/2 EPCORE NHL-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Raul Cordoba, MD, PhD

Articles

Combination Treatment With Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) and Zanubrutinib Induces High Rate of Complete Remission for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Dr. Cordoba on the Efficacy of Epcoritamab in DLBCL